17,261 trials
Chronic Hepatitis C · Hepatitis C Virus
Primary: The Percentage of Subjects Who Achieve 12-week Sustained Virologic Response (SVR12) — 90 percentage of participants
Multiple Myeloma
Primary: Percentage of Participants With Overall Response — 11.1; 29.2 percentage of participants
Rift Valley Fever
Primary: Safety as Measured by the Number of Adverse Events — 22; 130 AEs
Cervical Adenocarcinoma · Cervical Adenosquamous Carcinoma · Cervical Small Cell Carcinoma
Primary: Tumor Response — 7.4 percentage of participants
HIV
Primary: Safety: Grade 2 or Higher Adverse Events — 64; 61; 56 participants — p=0.88
Non Small Cell Lung Cancer (NSCLC)
Primary: Overall Survival (OS) — 19.4 months
Lung Cancer
Primary: Confirmed Response Rate (Complete Response and Partial Response) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) (Phase II Patients Only) — 19; 20…
Morbid Obesity
Primary: Primary Outcome: Change in Body Weight — 9.6 kg
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 12 — 7.90; 7.97; 7.91; 7.88 percentage of hemoglobin — p=0.4468
Chronic Obstructive Pulmonary Disease
Primary: Change From Baseline in 24-Hour Mean Heart Rate Post-dose — -0.19; -1.84; 0.40; -0.09 bpm
Nicotine Dependence · Alcohol Dependence
Primary: 4-week Continuous Abstinence From Smoking — 7.9; 10.6 percentage of participants abstinent
Lung Cancer
Primary: Progression-free Survival — 3.4; 4.1 months
Mantle Cell Lymphoma
Primary: Maximum Tolerated Dose of Lenalidomide Combined With Bortezomib and Rituximab in Phase I Participants — 10 mg lenalidomide, orally, daily, day 1-14
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 12 — 8.01; 8.00; 7.80; 8.15 percentage of hemoglobin — p=0.5206
Lupus Erythematosus, Systemic
Primary: Change From Baseline Serum Interleukin 6 (IL-6) Levels at the End of Active Dosing, Comparing Treatment to Placebo Cohort. — 1.6; 987.7; -82.5; -29.7 percentage change…